Taylor & Francis Group
Browse
tbsd_a_1724567_sm2739.pdf (524.98 kB)

Assessment of the hypoglycemic effect of Bixin in alloxan-induced diabetic rats: in vivo and in silico studies

Download (524.98 kB)
Version 3 2021-02-08, 11:46
Version 2 2020-02-14, 06:28
Version 1 2020-02-07, 08:55
journal contribution
posted on 2021-02-08, 11:46 authored by Hady Keita, Cleydson Breno Rodrigues dos Santos, Matheus Mercês Ramos, Elias Carvalho Padilha, Rodolfo Bortolozo Serafim, Andres Navarrete Castro, Jesus Rafael Rodriguez Amado, Gabriel Monteiro da Silva, Irlon Maciel Ferreira, Silvana Giuliatti, José Carlos Tavares Carvalho

The objectives of this study were to extract and purify Bixin from the seeds of Bixa orellana and to evaluate its hypoglycemic activity in vivo, as well as, to conduct an in silico study of selectivity on peroxisome proliferator-activated receptors via molecular docking and molecular dynamics simulations. Oral administration of Bixin (10 mg/kg) significantly reduced their glucose level that was alloxan-induced diabetic rats. Bixin showed in silico selectivity on peroxisome proliferator-activated receptors (PPARs), particularly by the peroxisome proliferator-activated receptor gamma (PPARγ), which supports the hypoglycemic activity of Bixin. From the results obtained, it can be inferred that Bixin presents hypoglycemic characteristics, which was confirmed by the results obtained from the in vivo and in silico tests. Bixin may act by other pathways to control blood glucose and thus it is possible that it presents a different toxicity profile than troglitazone, rosiglitazone and pioglitazone. However, more studies on the activity and toxicity of Bixin are needed to evaluate for further clinical use.

Communicated by Ramaswamy H. Sarma

Funding

The authors thank CAPES - PNPD/CAPES (Program/Project: PNPD/20130076-14001012005P1), Procad Amazonia Proc. Auxpe - 1723/2018 and National Council for Scientific and Technological Development – CNPq – RAPBioFar Proc. 407768/2013-0 for the financial support.

History